Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Macrophage link to hypertension
Thurs Jan 17th - Macrophages in the immune system may have a key role in hypertension, according to a project in Edinburgh, UK. More
Haemochromatosis gene’s impact on carriers
Thurs Jan 17th - A genetic variant that causes haemochromatosis is more dangerous than previously thought, according to a new UK analysis. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...

Cardiovascular care follow-up concerns

Thursday January 18th, 2018

European countries are “losing” many patients with chronic cardiovascular disease unnecessarily, according to a major analysis published today.

Researchers found that nearly 25% of these patients are back in hospital or dead within six months of diagnosis – usually because of cardiovascular disease.

The research involved patients at 100 hospitals and clinics in ten European countries and was backed by the European Society of Cardiology.

It was published as a UK analysis, simultaneously, raised concerns about the extent to which patients get access to cardiac rehabilitation programmes.

The European study involved some 2,420 patients with stable coronary disease or peripheral artery disease.

Age was a significant risk factor for rehospitalisation or death – as were peripheral revascularisation, chronic kidney disease and COPD. Living in a southern European country – on the edge of the Mediterranean - was associated with reduced risk.

The study found a significant drop in the taking of anti-hypertension drugs and of aspirin six months after patients were first treated.

Researcher Professor Michel Komajda, of the University Pierre and Marie Curie and Pitié-Salpêtrière Hospital in Paris, France, said: “In absolute numbers the reductions were modest but they did reach statistical significance. This shows that patients have a better chance of receiving recommended medications while in hospital or directly after an outpatient appointment.

“Six months later, drugs they should be taking to reduce the risk of death and rehospitalisation are prescribed less frequently. It is likely that there is insufficient handover of these patients to a cardiologist or GP and so their prescriptions are not renewed.”

Meanwhile in the UK, the National Audit of Cardiac Rehab, conducted by the British Heart Foundation, reported that 68,000 patients missed out on cardiac rehabilitation in one year – 48% of those eligible.

The study found that almost half of those who received rehabilitation had to wait longer than the recommended 28 days.

BHF chief executive Simon Gillespie said: “It is hugely encouraging that overall more patients are accessing cardiac rehabilitation services but half of heart attack survivors are still missing out on this potentially lifesaving service.

“Tens of thousands of people are therefore at greater risk of suffering another deadly heart attack.”

Komajda M, et al. The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. European Journal of Preventive Cardiology 18 January 2018; doi: 10.1177/2047487317751955

Tags: Europe | Heart Health | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)